Neurosom Electric Sleep Therapy

04/21/2026

Excited to be a part of Portland Startup Week next month, and especially this panel May 13th: Building Here: Healthcare Innovation and Oregon's Next Chapter!

Portland Startup Week is coming up May 11-16th. I'll be attending this event, "Building Here: Healthcare Innovation and Orergon's Next Chapter featuring Holly Rockweiler of Madorra Inc., Corin Tucker of Neurosom®, Philip Barish of OHSU Innovates and Dave Sanders, MD of CodyMD — details below ⬇....

04/02/2026

This week, Dr. Don Tucker, Chief Science Officer and Founder of Neurosom, presented this poster (https://lnkd.in/gD6kS-aR) at the Oxford Glymphatic & Brain Clearance Symposium. The article, "tES-Synchronized N3 Sleep Decreases Skin-Corrected Brain Impedance: Toward Multimodal, Model-Based Glymphatic Biomarkers" (Schofner et al., 2026) has been accepted for publication in SLEEP, the official journal of the Sleep Research Society. The takeaway? Results support enhanced glymphatic transport during stimulated N3 sleep.
What does this mean? With the tES stimulation of the Sleep WISP, there is a measurable decrease in resistance of the brain tissue (brain impedance) and an increase in the extracellular space (ECS) of the brain, which is the volume of liquid between the cells. This liquid, CSF (cerebrospinal fluid), is the fluid that can wash the brain of neurotoxins such as Amyloid-beta and tau that contribute to Alzheimer's Disease and other dementias. The proper clearance of these metabolite toxins can be called glymphatic clearance or transport, and the lack of clearance is termed glymphatic failure.
Our scientists are committed to following these early positive results with further studies, such as our current NIA-funded clinical trial for Mild Cognitive Impairment. We are building a future in which Neurosom cognitive care reduces the risk of dementia and promotes healthy brain aging.
Visit us: https://www.neurosom.net/

03/31/2026

Oxford Glymphatic & Brain Clearance Symposium 2026 is taking place this week at Keble College, Oxford. Neurosom scientists Don Tucker and Phan Luu are attending and presenting a poster, "tES-Synchronized N3 Sleep Decreases Skin-Corrected Brain Impedance: Toward Multimodal, Model-Based Glymphatic Biomarkers" (Schofner et al., 2026), SLEEP (accepted for publication).
Seated at the panel table is Dr. Maiken Nedergaard, M.D., D.M.Sc., widely regarded as the discoverer of the glymphatic system of the brain, or the pathway to waste clearance. Dr. Nedergaard's work is celebrated for uncovering the idea that the brain "washes" itself during sleep of metabolic waste that contributes to neurodegenerative diseases like Alzheimer's and other dementias.
Visit us: https://www.neurosom.net/

03/26/2026

Neurosom scientist to present a poster at Glymphatic Clearance Symposium. https://lnkd.in/gPAZV7zJ
Next week at the Oxford Glymphatic Clearance Symposium (March 30-April 1), Dr. Don Tucker will present, "tES Synchronization of Slow Oscillations in N3 Sleep Decreases Brain Electrical Impedance: Implications for Improved Brain Waste Clearance", a poster based on a paper accepted for publication in SLEEP, the official publication of the Sleep Research Society.
The Glymphatic Clearance Symposium brings together the foremost researchers in the field, including a keynote address by neuroscientist Maiken Nedergaard, M.D., D.M.Sc., widely regarded as the discoverer of the glymphatic system, the brain's waste-clearing pathway.
Visit us: https://www.neurosom.net/

03/24/2026

Thank you, LSI 'USA '26, for so many meaningful connections last week for our CEO, Viral Sheth, with the trailblazers of the medical device community. Highlights included sitting down with folks at the investor breakfast, 🍳🍽️🥞, Pub Trivia night, 🤔💭, and the Moonlight Chat.⏾ Oh, and the weather was not bad either!
Looking forward to the next meeting. Until then, be well and rest well.
https://lnkd.in/e3i2RFVR
Visit us: https://www.neurosom.net/

03/19/2026

Great meetings for our CEO, Viral Sheth, so far at LSI ’26—meeting new faces and making important connections. We’re grateful to reconnect with familiar colleagues and to make new friends while sharing our vision for better cognitive health and reduced dementia risk with the Sleep WISP® therapy system.
This year, we arrived at LSI with strong momentum, including: an oversubscribed bridge funding round as the company advances toward a seed round in the first half of 2026; patent allowance for Sleep WISP® to measure brain impedance in relation to extracellular space and to index metabolic waste clearance; a new publication accepted in SLEEP Journal titled “tES Synchronization of Slow Oscillations in N3 Sleep Decreases Brain Electrical Impedance: Implications for Improved Brain Waste Clearance”; recognition as the winner of the 2025 Oregon Entrepreneurs Network Angel Oregon Life & BioScience Award; and the launch of a second Parkinson’s disease study at Mount Sinai using the Sleep WISP®.
https://lnkd.in/e3i2RFVR
Visit us: https://www.neurosom.net/

03/18/2026

https://www.facebook.com/share/p/1AoR3sDTQx/

SLEEP, the Journal of the Sleep Research Society, accepted for publication on March 13, 2026, 'tES Synchronization of Slow Oscillations in N3 Sleep Decreases Brain Electrical Impedance: Implications for Improved Brain Waste Clearance', by Schofner et al. (2026)
The publication abstract states, "Sleep appears to be a critical period for the brain’s removal of metabolic waste products through its lymph system, which involves both perivascular cerebrospinal fluid (CSF) flow, transport of CSF through the extracellular space of the parenchyma, and glial (aquaporin 4 end feet) transfer across the blood-brain barrier. The decline of waste removal with the decline of stage N3 sleep in aging may be relevant to the neurodegeneration leading to dementia. The present results suggest that tES strategically applied at key sleep stages, such as the N2-N3 transition, may not only enhance the duration of N3 and REM sleep, but may facilitate the transient ECS expansion driven by cardiac pulses and respiration that supports brain waste clearance in healthy sleep."
The research analyzed in this publication was conducted using the Neurosom Sleep WISP®, a wearable EEG/tES sleep-therapy headband designed to increase time spent in deep sleep and improve cognitive health.
The authors of this publication include Steven Shofner, Kyle Morgan, Phan Luu, Roma Shusterman, Alexei Doncov, Jeff Heys, Lori Ray, Dr. Miranda Lim, M.D., Ph.D. (OHSU) and Don Tucker.
Read more:https://www.bel.company/s/SLEEP-2025-1133R3_Proof_fl.pdf

03/17/2026

Neurosom® is pleased to announce that a generous donor has funded a new Parkinson’s disease study at the Icahn School of Medicine at Mount Sinai to continue research using the Sleep WISP® therapy system. The study will be supported by the Glickenhaus Research Scholar Award and will be led by Dr. Allison C. Waters, PhD, Director of the Waters Lab within the Nash Family Center for Advanced Circuit Therapeutics and Medical Advisor to Neurosom, in collaboration with a multidisciplinary clinical team including Dr. Joohi Jimenez-Shahed, Dr. Emmanuel During, MD, and Dr. Rachel Fremont.
The Neurosom Sleep WISP® is a wearable EEG/tES sleep therapy system designed for use at home and built to support cognitive health. The system uses AI to track sleep stages in real time and delivers gentle stimulation designed to lengthen deep sleep, enabling personalized treatment for greater clearance of metabolic brain waste.
A recent publication by Dr. Waters and colleagues in Clinical Parkinsonism & Related Disorders, titled “Emerging neurotechnological approaches to management of sleep disturbances in Parkinson’s disease,” reviews the growing role of neurotechnology in addressing sleep dysfunction in PD. The authors note that sleep disturbance is among the most common and debilitating non-motor symptoms of Parkinson’s disease. Increasing evidence suggests that disrupted sleep not only reduces quality of life but may also interact with the underlying neurodegenerative process. The paper highlights research indicating that degradation of healthy sleep is closely linked with disease progression and may reflect overlapping biological mechanisms between early synuclein pathology and disrupted sleep architecture. The authors conclude that integrating emerging sleep neurotechnologies with comprehensive monitoring of sleep physiology may enable therapeutic programs capable of improving sleep and potentially slowing disease progression in Parkinson’s disease.
Dr. Waters emphasized the broader significance of the work:
“Neurology is entering an era where we can measure brain states in real time and intervene precisely. Sleep WISP is an example of that future. By detecting deep sleep and gently synchronizing the brain’s slow oscillations, we can begin to engineer healthier sleep in people living with Parkinson’s disease.”
The new Mount Sinai study will further investigate whether enhancing deep sleep through closed-loop neuromodulation can improve sleep quality and downstream health outcomes in people with Parkinson’s disease. The project brings together expertise in sleep medicine, movement disorders, psychiatry, and neurotechnology to evaluate both feasibility and therapeutic potential in real-world home settings.
Neurosom is proud to support this collaborative effort and to continue advancing research aimed at improving the lives of people living with Parkinson’s disease through innovative sleep-focused neurotechnology.

03/12/2026

Neurosom's CEO and founder, Viral Sheth, is excited to present at '26 USA next week. https://www.lsiusasummit.com/
- Neurosom's mission is to improve aging, brain health, and reduce the risk of dementia through noninvasive sleep therapy.
- The Sleep WISP headband uses AI to track EEG stages and apply personalized gentle stimulation to optimize deep sleep, comfortably used at home.
- The company won the Investment from the Angel Oregon Life and BioScience Award Program in December, recognizing its innovation and clinical potential.
- Neurosom led a successful oversubscribed bridge round shortly after the AOBIO award win.
- The company received FDA clearance in 2025 for NEAT AI-powered software, which accurately assesses the sleep stages and programs personalized therapy.
- The Sleep WISP has also received a patent allowance for measuring Glymphatic Clearance Capacity through skin-brain impedance measures, adding the ability to not only register the change in glymphatic waste clearance in the brain, but also to improve glymphatic flow through the stimulation of the Sleep WISP.
Visit us: https://www.neurosom.net/

03/05/2026

Neurosom is attending and sponsoring the Oxford Glymphatic & Brain Clearance Symposium, March 30 – April 1st.
https://oxfordglymphaticsymposium.co.uk/
Dr. Don Tucker, PhD, Chief Scientific Officer, and Dr. Phan Luu, Chief Technology Officer, of Neurosom will attend the Oxford Glymphatic & Brain Clearance Symposium. Neurosom is also a proud sponsor of the conference. The second annual Symposium, this year held at Oxford's prestigious Keble College, will bring together leading experts on glymphatic clearance, including keynote speaker Dr. Maiken Nedergaard, D.MSc., considered to be the discoverer of the "glymphatic system." Program topics will include sleep-related physiology, pathways for CSF clearance, and valid measures of glymphatic function.
Visit us: https://www.neurosom.net/